US OptionsDetailed Quotes
OCGN241220C2000
- 0.04
- 0.000.00%
15min DelayClose Nov 25 16:00 ET
0.00High0.00Low
0.04Open0.04Pre Close0 Volume291 Open Interest2.00Strike Price0.00Turnover236.24%IV121.26%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.04Extrinsic Value100Contract SizeAmericanOptions Type0.1705Delta0.4487Gamma23.06Leverage Ratio-0.0029Theta0.0001Rho3.93Eff Leverage0.0006Vega
Ocugen Stock Discussion
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate Ocu410St for Treatment of Abca4-Associated Retinopathies Including Stargardt Disease
Ocugen Announces Compelling Preliminary Data for Ocu410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
No comment yet